Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 18/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | TP53 | P04637 | 2/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | GMNN | O75496 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | THRB | P10828 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | BLM | P54132 | 1/20 | 0.62 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29389782 | 0.90 | ADORA3 (0.83) | ADORA3CYP3A4TSHRNFKB1ADORA1 | |
| SCHEMBL935050 | 0.90 | ADORA3 (0.83) | ADORA3CYP3A4TSHRNFKB1ADORA1 | |
| SCHEMBL6210936 | 0.87 | ADORA3 (0.84) | ADORA3MAPK1MAPTTP53NPC1 | |
| SCHEMBL6482676 | 0.84 | ADORA3 (0.80) | ADORA3MAPK1MAPTTP53NPC1 | |
| SCHEMBL6482789 | 0.83 | ADORA3 (0.83) | ADORA3MAPK1MAPTTP53NPC1 | |
| SCHEMBL19459489 | 0.83 | ADORA3 (0.82) | ADORA3CYP3A4TSHRNFKB1ADORA1 | |
| SCHEMBL24615060 | 0.82 | ADORA3 (0.76) | ADORA3MAPK1MAPTALDH1A1LMNA | |
| SCHEMBL7512284 | 0.81 | ADORA3 (0.69) | ADORA3ADORA1ADORA2A | |
| SCHEMBL24601196 | 0.81 | ADORA3 (0.58) | ADORA3MAPK1MAPTTP53NPC1 | |
| SCHEMBL937053 | 0.80 | ADORA3 (0.73) | ADORA3ADORA1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050171049-A1 | Compounds for the treatment of ischemia | DENINNO MICHAEL P (US) | 2005-08-04 | — | — | US | claimed |
| US-20030055021-A1 | Compounds for the treatment of ischemia | PFIZER, INC. | 2003-03-20 | — | — | US | claimed |
| EP-1241176-A1 | Purine derivatives for the treatment of ischemia | Pfizer Products Inc. (US) | 2002-09-18 | — | — | EP | claimed |
| US-20050171049-A1 | Compounds for the treatment of ischemia | DENINNO MICHAEL P (US) | 2005-08-04 | — | — | US | disclosed |
| US-20030055021-A1 | Compounds for the treatment of ischemia | PFIZER, INC. | 2003-03-20 | — | — | US | disclosed |
| EP-1241176-A1 | Purine derivatives for the treatment of ischemia | Pfizer Products Inc. (US) | 2002-09-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171049-A1 | Compounds for the treatment of ischemia | TNNI3, ADRB3, TBXA2R | ADORA3 4/4885MAPK1 3833/4885MAPT 4820/4885 |
| US-20030055021-A1 | Compounds for the treatment of ischemia | TNNI3, ADRB3, FABP3 | ADORA3 29/4885MAPK1 2593/4885MAPT 4649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.